Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

What's the potential of Global Blood Therapeutics’ Voxelotor (GBT440) in sickle cell disease after data released at ASH 2017

Ticker(s): GBT

Who's the expert?

Name: Dr John Strouse - MD

Institution: Duke University

  • Associate Professor of Medicine and Pediatrics and Director of the Adult Sickle Cell Program at Duke University.
  • Currently cares for 200 patients with Sickle Cell Disease (100 children & 100 adults) and15 patients with hereditary hemochromatosis.
  • Research has focused on the epidemiology, risk factors, and prevention of the pulmonary and central nervous system complications of sickle cell disease and includes retrospective and prospective cohort studies and clinical trials; local site co-investigator on trials for GBT-440 and rivapansel.

Interview Questions
Q1.

Can you describe your experience treating patients with sickle cell disease? What is the first line of therapy that you use, and what are the pros and cons of each of those treatments? 

Added By: c_admin
Q2.

Can you describe mechanism of action for GBT440? Are there any other hemoglobin oxygen affinity modulators out there, and how do they differ from GBT440? From a mechanistic perspective, how does GBT440 relieve sickle cell crises and pain? 

Added By: c_admin
Q3.

The Phase1/2 study showed that 46% of patients in the treatment group demonstrated an increase in hemoglobin (greater than 1 g/dL increase). How meaningful are these results for you?

Added By: c_admin
Q4.

In a case study of a male age 67, reductions were observed in reticulocyte count and bilirubin, and blood oxygen levels were up from 86mmHg at baseline to 96mmHg at 65 weeks. Are those clinically significant results, and if so, what is the likelihood of this being replicated across all patients of all ages in the HOPE studies?

Added By: c_admin
Q5.

On a scale from 1-10, 10 being extremely excited, how would you rate your level of excitement for this drug?

Added By: c_admin
Q6.

What is the typical treatment regimen of your current patient population? Assuming Voxelotor is approved how likely will the prescribing community switch to Voxelotor or will there be a gradual shift as consensus builds for the products use? 

Added By: alexander poulos
Q7.

How much of a competitive threat do you view Lentiglobin assuming bluebird bio is successful in bringing it to market?

Added By: alexander poulos

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.